NASDAQ · NRXP
Healthcare · Biotechnology
$2.24
Up+$0.15 (+6.47%)
Updated Nov 4, 2026, 5:05 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NRXP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
NRXP closed at $2.24 after 21 trading sessions, down 23.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.165 | $2.34 | $2.11 | $2.24 | 1.8M |
| Nov 2, 2026 | $2.32 | $2.44 | $2.14 | $2.17 | 2.51M |
| Oct 30, 2026 | $2.83 | $2.84 | $2.11 | $2.27 | 15.64M |
| Oct 29, 2026 | $2.70 | $2.7732 | $2.615 | $2.66 | 1.76M |
| Oct 28, 2026 | $2.73 | $2.7449 | $2.64 | $2.69 | 834.66K |
| Oct 27, 2026 | $2.59 | $2.705 | $2.53 | $2.69 | 749.68K |
| Oct 26, 2026 | $2.48 | $2.59 | $2.459 | $2.55 | 594.73K |
| Oct 23, 2026 | $2.36 | $2.50 | $2.24 | $2.49 | 840.3K |
| Oct 22, 2026 | $2.57 | $2.6099 | $2.36 | $2.40 | 1.05M |
| Oct 21, 2026 | $2.65 | $2.70 | $2.61 | $2.63 | 526.55K |
| Oct 20, 2026 | $2.63 | $2.77 | $2.545 | $2.62 | 1.35M |
| Oct 19, 2026 | $2.815 | $2.815 | $2.6228 | $2.63 | 1.09M |
| Oct 16, 2026 | $2.70 | $2.76 | $2.572 | $2.60 | 1.23M |
| Oct 15, 2026 | $2.53 | $2.7718 | $2.48 | $2.71 | 1.18M |
| Oct 14, 2026 | $2.64 | $2.705 | $2.56 | $2.59 | 696.34K |
| Oct 13, 2026 | $2.85 | $2.85 | $2.675 | $2.70 | 553.87K |
| Oct 12, 2026 | $2.85 | $2.93 | $2.8145 | $2.85 | 481.04K |
| Oct 9, 2026 | $2.89 | $2.89 | $2.82 | $2.85 | 289.41K |
| Oct 8, 2026 | $2.88 | $2.895 | $2.805 | $2.89 | 651.77K |
| Oct 7, 2026 | $2.88 | $2.93 | $2.87 | $2.90 | 405.07K |
| Oct 6, 2026 | $2.89 | $2.975 | $2.825 | $2.94 | 418.91K |
The latest Smart Investors Daily articles mentioning NRXP.
Company
Market Activity
Research & News
NRXP research
Company profile and research snapshot.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Ascendiant Capital | Buy | — |
| Oct 1, 2026 | Ascendiant Capital | Buy | — |
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 30, 2026
The approval comes ahead of the FDA-announced November 10, approval goal date.Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic
Benzinga · Oct 30, 2026
NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.
Yahoo · Oct 29, 2026
Company to issue press release before market open; conference call to follow at 8:30 a.m. ETWILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announced that it will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss a regulatory milestone f
Yahoo · Oct 19, 2026
Key Takeaways; Cannabis Sector Aurora Cannabis Rejected Curaleaf’s $5-a-Share Takeover Bid, Despite Exploring Alternatives Cronos Group Completed €57.5 Million Acquisition of Dutch Cannabis Producer CanAdelaar Tilray Medical Secured Portuguese Approval for In-House Cannabis Quality Testing Key Takeaways; Psychedelic Sector Optimi Health Championed Natural Psilocybin Growth at ThinkEquity Conference NRx Pharmaceuticals Received FDA Letter Requesting Minor […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NRXP.
